Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.

about

Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.

Item

http://www.wikidata.org/entity/Q38747272

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Population pharmacokinetic ana ...... or refractory women's cancers.

@en

type

Item

label

Population pharmacokinetic ana ...... or refractory women's cancers.

@en

prefLabel

Population pharmacokinetic ana ...... or refractory women's cancers.

@en

P1476

Population pharmacokinetic ana ...... or refractory women's cancers

@en

P2093

Christina M Annunziata

http://www.w3.org/2001/XMLSchema#string

Cody J Peer

http://www.w3.org/2001/XMLSchema#string

Elise C Kohn

http://www.w3.org/2001/XMLSchema#string

Jeffers Nguyen

http://www.w3.org/2001/XMLSchema#string

Jeffrey Roth

http://www.w3.org/2001/XMLSchema#string

Jung-Min Lee

http://www.w3.org/2001/XMLSchema#string

Lori Minasian

http://www.w3.org/2001/XMLSchema#string

Louis Rodgers

http://www.w3.org/2001/XMLSchema#string

William D Figg

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.

The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.

P2888

s00280-017-3346-1

P304

165-175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-017-3346-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085756611

http://www.w3.org/2001/XMLSchema#string

P698

28577239

http://www.w3.org/2001/XMLSchema#string

P932

6361113

http://www.w3.org/2001/XMLSchema#string